In current clinical trials of CD19 CAR T cell therapy for ALL, CD19-28ζ CAR T cells can exist in vivo for a median time of 3 months, while 68% of patients infused with CD19-BBζ CAR T cells exhibit cell survival for over 6 months [11]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.